Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 4/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 4/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HCAR3 | P49019 | 3/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | CCNK | O75909 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25411503 | 1.00 | BTK (0.40) | BTKMAP4K4JAK3HSD11B1HCAR3 | |
| SCHEMBL1514204 | 0.93 | GFER (0.38) | BTKJAK3HCAR3SMN1; SMN2 | |
| SCHEMBL1514207 | 0.93 | GFER (0.38) | BTKJAK3HCAR3SMN1; SMN2 | |
| SCHEMBL15971751 | 0.93 | MAP4K4 (0.42) | BTKMAP4K4HCAR3POLBTXNRD1 | |
| SCHEMBL15971753 | 0.93 | MAP4K4 (0.42) | BTKMAP4K4HCAR3POLBTXNRD1 | |
| SCHEMBL30533346 | 0.84 | ALDH1A1 (0.44) | BTKMAP4K4L3MBTL1MAPK1 | |
| SCHEMBL30533311 | 0.84 | ALDH1A1 (0.44) | BTKMAP4K4L3MBTL1MAPK1 | |
| SCHEMBL25408233 | 0.80 | GSK3B (0.39) | BTKJAK3HSD11B1SMN1; SMN2CCNK | |
| SCHEMBL25408577 | 0.80 | GSK3B (0.39) | BTKJAK3HSD11B1SMN1; SMN2CCNK | |
| SCHEMBL15985109 | 0.80 | ALDH1A1 (0.51) | MAP4K4L3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | Facio Intellectual Property B.V. (NL) | 2023-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271953-A1 | Novel compounds for treatment of diseases related to DUX4 expression | UTRN, ZFX, CBX6 | BTK 4818/4885MAP4K4 2954/4885JAK3 4676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.